drugset / Trial / NCT00503880

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

NCT00503880

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow or in peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving clofarabine and cytarabine together with G-CSF may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine and to see how well it works when given together with cytarabine and G-CSF in treating patients with myelodysplastic syndromes.

Timeline

Start
2007-05-07
Primary completion
2009-10-13
Completion
2009-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 10 mg/m2 Intravenous
Background Cytarabine Small molecule 10 mg/m2 Subcutaneous
Background filgrastim Protein / enzyme biologic 300 ug Subcutaneous